Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer

References

• Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009;20:1499–504.
   PubMed Web of Science ®Google Scholar
• Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14:2584–9.
   PubMed Web of Science ®Google Scholar
• Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat 2011;129:761–5.
   PubMed Web of Science ®Google Scholar
• Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61–6.
   PubMed Web of Science ®Google Scholar
• Chia S. Testing for discordance at metastatic relapse: Does it matter?. J Clin Oncol 2012;30:575–6.
   PubMed Web of Science ®Google Scholar
• Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. Lancet Oncol 2009;10:933–5.
   PubMed Web of Science ®Google Scholar
• Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003;14:S199–202.
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol 2008;26:1404–10.
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, et al. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 2011;4:1181–9.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784–95.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010;15:1164–8.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125–30.
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032–8.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes – dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–47.
   PubMed Web of Science ®Google Scholar
• Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601–8.
   PubMed Web of Science ®Google Scholar
• Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012;30:593–9.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011;22: 2227–33.
   PubMed Web of Science ®Google Scholar
• Gong Y, Han EY, Guo M, Pusztai L, Sneige N. Stability of estrogen receptor status in breast carcinoma: A comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 2011;117:705–13.
   PubMed Web of Science ®Google Scholar
• Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, et al. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012; 38:708–14.
   PubMed Web of Science ®Google Scholar
• Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: Clinical implications of progesterone receptor loss. Virchows Arch 2011;459:1–10.
   PubMed Web of Science ®Google Scholar
• Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al. HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression. Breast Cancer Res Treat 2011;125:553–61.
   PubMed Web of Science ®Google Scholar
• Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010;28:15s (Abstract 1009).
   PubMedGoogle Scholar
• Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010;21:1254–61.
   PubMed Web of Science ®Google Scholar
• Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010;133:416–29.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953–8.
   PubMed Web of Science ®Google Scholar
• Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301–6.
   PubMed Web of Science ®Google Scholar
• Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: Discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557–62.
   PubMed Web of Science ®Google Scholar
• Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008;122:999–1004.
   Google Scholar
• Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31.
   PubMed Web of Science ®Google Scholar
• Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90:65–70.
   PubMed Web of Science ®Google Scholar
• Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90: 2344–8.
   PubMed Web of Science ®Google Scholar
• Edgerton SM, Moore D 2nd,Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214–21.
   PubMedGoogle Scholar
• Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036–43.
   PubMed Web of Science ®Google Scholar
• Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141–6.
   PubMed Web of Science ®Google Scholar
• Mobbs BG, Fish EB, Pritchard KI, Oldfield G, Hanna WH. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: Influence of time and treatment. Eur J Cancer Clin Oncol 1987;23:819–26.
   PubMedGoogle Scholar
• Sharma A, Crook T, Thompson A, Palmieri C. Surgical oncology: Why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol 2010;7:72–4.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000;156:1505–13.
   PubMed Web of Science ®Google Scholar